Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule Janus kinase inhibitor |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA37
|
| gptkbp:brand |
gptkb:Olumiant
|
| gptkbp:CASNumber |
1187594-09-7
|
| gptkbp:developer |
gptkb:Eli_Lilly_and_Company
gptkb:Incyte |
| gptkbp:eliminationHalfLife |
12 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C16H17N7O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
baricitinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
JAK1 inhibitor
JAK2 inhibitor |
| gptkbp:metabolism |
minimal
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
50%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
thrombosis infections increased liver enzymes |
| gptkbp:usedFor |
gptkb:COVID-19
rheumatoid arthritis alopecia areata |
| gptkbp:bfsParent |
gptkb:COVID-19_treatments
|
| gptkbp:bfsLayer |
6
|